Idiopathic pulmonary fibrosis: Current understanding of the pathogenesis and the status of treatment

CMAJ. Canadian Medical Association Journal

Volumn 171, Issue 2, 2004, Pages 153-160

  Khalil, Nasreen ^a,c   O'Connor, Robert ^b  

^a VANCOUVER COASTAL HEALTH RESEARCH INSTITUTE   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c JACK BELL RESEARCH CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; ANTIFIBROTIC AGENT; AZATHIOPRINE; BETA1A INTERFERON; BOSENTAN; CALCIUM; CAPTOPRIL; COLCHICINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DECORIN; GAMMA1B INTERFERON; IMMUNOSUPPRESSIVE AGENT; KERATINOCYTE GROWTH FACTOR; NICOTINIC ACID; PENICILLAMINE; PIRFENIDONE; PREDNISOLONE; PREDNISONE; SYNTHETIC PEPTIDE; TAURINE; VITAMIN D;

BLOOD ANALYSIS; BONE MARROW SUPPRESSION; CLINICAL FEATURE; CLINICAL TRIAL; DIAGNOSTIC IMAGING; DIAGNOSTIC PROCEDURE; DRUG RESPONSE; EPIDEMIOLOGICAL DATA; HUMAN; IDIOPATHIC DISEASE; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY DYSFUNCTION; LABORATORY TEST; LIVER TOXICITY; LUNG BIOPSY; LUNG FIBROSIS; LUNG FUNCTION TEST; OSTEOPOROSIS; PATHOGENESIS; PATIENT CARE; REVIEW; SIDE EFFECT; TREATMENT INDICATION; ADULT; AGED; CLASSIFICATION; FEMALE; INTERSTITIAL LUNG DISEASE; MALE; MIDDLE AGED; PATHOLOGY; PATHOPHYSIOLOGY; PREVALENCE;

ADULT; AGED; FEMALE; HUMANS; LUNG DISEASES, INTERSTITIAL; MALE; MIDDLE AGED; PREVALENCE; PULMONARY FIBROSIS; RESPIRATORY FUNCTION TESTS;

EID: 3442888549     PISSN: 08203946     EISSN: None     Source Type: Journal    
DOI: 10.1503/cmaj.1030055     Document Type: Review

References (93)

1. Katzenstein AL, Myers JL. Nonspecific interstitial pneumonia and the other idiopathic interstitial pneumonias: classification and diagnostic criteria. Am J Surg Pathol 2000;24:1-3.
2. Katzenstein AL, Zisman DA, Litzky LA, Nyuyen BT, Kotloff RM. Usual interstitial pneumonia: histologic study of biopsy and explant specimens. Am J Surg Pathol 2002;26:1567-77.
3. American Thoracic Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. Am J Respir Crit Care Med 2000;161:646-64.
4. American Thoracic Society. ATS/ERS international consensus classification of idiopathic interstitial pneumonias. Am J Respir Crit Care Med 2002;165:277-304.
5. Epler GR, Colby TV, McCloud TC, Carrington CB, Gaensler EA. Bronchiolitios obliterans organizing pneumonia. N Engl J Med 1985;312:152-8.
6. Latsi PI, du Bois RM, Nicholson AG, Colby TV, Bisirtzoglou D, Nikolakopopoulou A, et al. Fibrotic idiopathic interstitial pneumonia: the prognostic value of longitudinal functional trends. Am J Respir Crit Care Med 2003; 168:531-7.
7. Collard HR, King TE, Bartelson BB, Vourlekis JS, Schwartz MI, Brown KK. Changes in clinical and physiological variables predict survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2003;168:538-42.
8. Flaherty KR, Mumford JA, Murray S, Kazerooni EA, Gross BH, Colby TV, et al. Prognostic implications of physiologic and radiologic changes in idiopathic interstitial pneumonia. Am J Respir Crit Care Med 2003;168:543-8.
9. Flaherty KR, Kazerooni EA, Gross BH, Toews GB, Colby TV, Travis WD, et al. Radiological versus histological diagnosis in UIP and NSIP: survival implications. Thorax 2003;58:143-8.
10. Katzenstein AL, Meyers JL. Idiopathic pulmonary fibrosis: clinical relevance of pathological classification. Am J Respir Crit Care Med 1998;157:1301-15.
11. Flaherty KR, Toews GB, Travis WD, Colby TV, Kazerooni EA, Gross BH, et al. Clinical significance of histological classification of idiopathic interstitial pneumonia. Eur Respir J 2002;19:275-83.
12. Travis WD, Matsui K, Moss JE, Ferrans VJ. Idiopathic nonspecific interstititial pneumonia: prognostic significance of cellular and fibrosing patterns. Survival comparison with usual interstitial pneumonia and desquamative interstitial pneumonia. Am J Surg Pathol 2000;24:19-33.
13. Hansell A, Hollowell J, Nichols T, McNiece R, Strachan D. Use of the General Practice Research Database (GPRD) for respiratory epidemiology: a comparison with the 4th Morbidity Survey in General Practice (MSGP4). Thorax 1999;54:413-9.
14. Coultas D, Zumwalt W, Black W, Sobonya R. The epidemiology of interstitial lung disease. Am J Respir Crit Care Med 1994;150:967-72.
15. Baumgartner KB, Samet JM, Stidley CA, Colby TV, Waldron JA. Cigarette smoking: a risk factor for idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 1997;155:242-8.
16. Baumgartner KB, Samet JM, Coultas DB, Stidley CA, Hunt WC, Colby TV, et al. Occupational and environmental risk factors for idiopathic pulmonary fibrosis: a mulricenter case-control study. Collaborating centres. Am J Epidemiol 2000;152:307-15.
17. Iwai K, Mori T, Yamada N, Yamaguchi M, Hosoda Y. Idiopathic pulmonary fibrosis: epidemiological approaches to occupational exposure. Am J Respir Crit Care Med 1994;150:670-5.
18. Egan JJ, Stewart JP, Hasleton PS, Arrand JR, Carroll KB, Woodcock AA. Epstein-Barr virus replication within pulmonary epithelial cells in cryptogenic fibrosing alveolitis. Thorax 1995;50:1234-9.
19. Pinsker KL, Schneyer B, Becker N, Kamholz SL. Usual interstitial pneumonia following Texas A2 influenza infection. Chest 1981;80:123-6.
20. Meliconi R, Andreone P, Fasano L, Galli S, Pacilli A, Miniero R, et al. Incidence of hepatitis C virus infection in Italian patients with idiopathic pulmonary fibrosis. Thorax 1996;51:315-7.
21. Jakab GJ. Sequential virus infections, bacterial superinfections, and fibrogenesis. Am Rev Respir Dis 1990;142:374-9.
22. Bitterman PB, Rennard SI, Keogh BA, Wewers MD, Adelberg S, Crystal RG. Familial idiopathic pulmonary fibrosis: evidence of lung inflammation in unaffected family members. N Engl J Med 1986;314:1343-7.
23. Verleden GM, du Bois RM, Bouros D, Drent M, Millar A, Muller-Quernheim J, et al. Genetic predisposition and pathogenetic mechanisms of interstitial lung diseases of unknown origin. Eur Respir J Suppl 2001;32:17s-29s.
24. Selman M, Lin HM, Montano M, Jenkins AL, Estrada A, Lin Z, et al. Surfactant protein A and B genetic variants predispose to idiopathic pulmonary fibrosis. Hum Genet 2003;113:542-50.
25. Whyte M, Hubbard R, Meliconi R, Whidborne M, Eaton V, Bingle C, et al. Increased risk of fibrosing alveolitis associated with interleukin-1 receptor antagonist and tumor necrosis factor-alpha gene polymorphisms. Am J Respir Crit Care Med 2000;162(2 Pt 1):755-8.
26. Zorzetto M, Ferrarotti I, Trisolini R, Agli LL, Scabini R, Novo M, et al. Complement receptor 1 gene polymorphisms are associated with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2003;168:330-4.
27. Streiter RM. Inflammatory mechanisms are not a minor component of the pathogenesis of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2002; 165:1206-7.
28. Crystal RG, Bitterman PB, Rennard SI, Hance AJ, Keogh BA. Interstitial lung diseases of unknown cause: disorders characterized by chronic inflammation of the lower respiratory tract. N Engl J Med 1994;310:154-66.
29. Selman M, King TE, Pardo A; American Thoracic Society; European Respiratory Society; American College of Chest Physicians. Idiopathic pulmonary fibrosis: prevailing and evolving hypotheses about its pathogenesis and implications for therapy. Ann Internal Med 2001;134:136-51.
30. Richeldi L, Davies HR, Ferrara G, Franco F. Corticosteroids for idiopathic pulmonary fibrosis. Cochrane Database Syst Rev 2003;3:CD002880.
31. Davies HR, Richeldi L, Walters EH. Immunomodulary agents for idiopathic pulmonary fibrosis. Cochrane Database Syst Rev 2003;3:CD003134.
32. Flaherty KR, Toews GB, Lynch JP 3rd, Kazerooni EA, Gross BH, Strawderman RL, et al. Steroids in idiopathic pulmonary fibrosis: a prospective assessment of adverse reactions, response to therapy, and survival. Am J Med 2001;110:278-82.
33. Xu Y, Hua J, Mui A, O'Connor R, Grotendorst G, Khalil N. Release of biologically active TGF-beta1 by alveolar epithelial cells results in pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol 2003;285:L527-39.
34. Munger JS, Huang X, Kawakatsu H, Griffiths MJ, Dalton SL, Wu J, et al. The integrin alpha v beta 6 binds and activates latent TGF-beta 1: a mechanism for regulating pulmonary inflammation and fibrosis. Cell 1999;96:319-28.
35. Majumdar S, Li D, Ansari T, Pantelidis P, Black CM, Gizycki M, et al. Different cytokine profiles in cyptogenic fibrosing alveolitis and fibrosing alveolitis associated with systemic sclerosis: a quantitative study of open lung biopsies. Eur Respir J 1999;14:251-7.
36. Khalil N, O'Connor R, Flanders K, Unruh H. TGF-beta1, but not TGF-beta 2 or TGF-beta 3, is differentially present in epithelial cells of advanced pulmonary fibrosis: an immunohistochemical study. Am J Respir Cell Mol Biol 1996;14:131-8.
37. Khalil N, O'Connor R, Unruh H, Warren P, Kemp A, Bereznay O, et al. Increased production and immunohistochemical localization of transforming growth factor-beta (TGF-beta) in idiopathic pulmonary fibrosis. Am J Respir Cell Mol Biol 1991;5:155-162.
38. Khalil N, Parekh TV, O'Connor R, Antman N, Kepron W, Yehaulaeshet T, et al. Regulation of the effects of TGF-beta 1 by activation of latent TGF-beta 1 and differential expression of TGF-beta receptors (T beta R-I and T beta R-II) in idiopathic pulmonary fibrosis. Thorax 2001;56:907-15.
39. Antoniades HN, Bravo MA, Avila RE, Galanopoulos T, Neville-Gordon J, Maxwell M. Platelet-derived growth factor in idiopathic pulmonary fibrosis. J Clin Invest 1990;86:1055-64.
40. Pan LH, Ohtani H, Yamauchi K, Nagwa H. Co-expression of TNF-alpha and IL-1 beta in human acute pulmonary fibrotic diseases: an immunohistochemical analysis. Pathol Int 1996;46:91-9.
41. Nash JR, McLaughlin PJ Butcher D, Corrin B. Expression of tumor necrosis factor-alpha in cryptogenic fibrosing aveolitis. Histopathol 1993;22:343-7.
42. Uh ST, Inoue Y, King TE Jr, Chan ED, Newman LS, Riches DW. Morphometric analysis of insulin-like growth factor-I localization in lung tissues of patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 1998; 158:1626-35.
43. Inoue Y, King TE Jr, Barker E, Daniloff E, Newman LS. Basic fibroblast growth factor and its receptors in idiopathic pulmonary fibrosis and lymphangioleiomyomatosis. Am J Respir Crit Care Med 2002;166:765-73.
44. Xu YD, Hua J, O'Connor R, Khalil N. Chronic release of active TFG-beta1 by alveolar epithelial cell (AEC) line, L-2 results in connective tissue (CT) synthesis and conversion of L-2 cells to a fibroblast-like phenotype. Am J Respir Crit Care Med 2003;167:A572.
45. Ramos C, Montano M, Garcia-Alvarez J, Ruiz V, Uhal BD, Selman M, et al. Fibroblasts from idiopathic pulmonary fibrosis and normal lungs differ in growth rate, apoptosis, and tissue inhibitor of metalloproteinases expression. Am J Respir Cell Mol Biol 2001;24:591-8.
46. Xu YD, Hua J, Chen G, Simon T, Mui A, Khalil N. Alveolar epithelial cells (AEC) of normal rat lung explants transfected with the retrovirus, pMX-Ls-223, 225-TGF-beta1 results in connective tissue (CT) synthesis and fibroblast proliferation. Am J Respir Crit Care Med. 2003;167:A568.
47. Furuie H, Yamansali H, Suga M, Ando M. Altered accessory cell function of alveolar macrophages: a possible mechanism for induction of Th2 secretory profile in idiopathic pulmonary fibrosis. Eur Respir J 1997;10:787-94.
48. Suveer S, du Bois R. Autoantibodies in cryptogenic fibrosing alveolitis. Respir Res 2001;2:61-3.
49. Schettino IA, Ab'Saber AM, Vollmer R, Saldiva PH, Carvalho CR, Kairalla RA, et al. Accuracy of high resolution CT in assessing idiopathic pulmonary fibrosis histology by objective morphometric index. Pathol Res Pract 2002;198:347-54.
50. Wells AU, Desai SR, Rubens MB, Goh NSL, Cramer D, Nicholson AG, et al. Idiopathic pulmonary fibrosis: a composite physiological index derived from disease extent observed by computed tomography. Am J Respir Crit Care Med 2001;167:962-9.
51. Johnston IDA, Prescott RJ, Chalmers JC, Rudd RM. British Thoracic Society study of cryptogenic fibrosing alveolitis: current presentation and initial management Thorax 1997;52:38-44.
52. Channick RN, Hoch RC, Newhart JW, Johnson FW, Smith CM. Improvement in pulmonary hypertension and hypoxemia during nitric oxide inhalation in a patient with end-stage pulmonary fibrosis. Am J Respir Crit Care Med 1994;149:811-4.
53. Ellis SM, Hansell DM. Idiopathic interstitial pneumonias imaging-pathology correlation. Eur Radiol 2002;12:610-26.
54. Hunninghake GW, Zimerman MB, Scwartz DA, King TE, Lynch J, Hegle R, et al. Utility of a lung biopsy for the diagnosis of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2001;164:193-6.
55. Raghu G, Mageto YN, Lockhart D, Schmidt RA, Wood DE, Godwin JD. The accuracy of the clinical diagnosis of new-onset idiopathic pulmonary fibrosis and other interstitial lung disease: a prospective study. Chest 1999;116:1168-74.
56. Primack SL, Mayo JR, Hartman TE, Miller RR, Muller NL. MRI of infiltrative lung disease: comparison with pathologic findings. J Comput Assit Tomogr 1994;18:233-8.
57. Jones HA, Boobis AR, Hamacher K, Coenen HH, Clark JC. PET imaging of pulmonary fibrosis. J Nucl Med 2003;44:483-4.
58. Alhamad EH, Lynch JP 3rd, Martinez FJ. Pulmonary function tests in interstitial lung disease: What role do they have? Clin Chest Med 2001;22:715-50.
59. Meliconi R, Bestagno M, Sturani C, Negri C, Galavotti V, Sala C, et al. Autoantibodies to DNA topoisomerism II in cryptogenic fibrosing alveolitis and connective tissue disease. Clin Exp Immunol 1989;76:184-9.
60. Pluss JL, West SG. Idiopathic pulmonary fibrosis associated with high-titer antibodies against ribonucleoprpotein (nRNP): report of 3 cases. J Am Ostopath Assoc 1986;86:735-42.
61. Costabel U, Guzman J. Bronchoalveolar lavage in interstitial lung disease. Curr Opin Pulm Med 2001;7:255-61.
62. Veeraraghavan S, Latsi PI, Wells AU, Pantelidis P, Nicholson AG, Colby TV, et al. BAL findings in idiopathic nonspecific interstitial pneumonia and usual interstitial pneumonia. Eur Respir J 2003;22:239-44.
63. Poletti V, Patelli M, Ferracini R, Simonetti M, Spiga L. Transbronchial lung biopsy in infiltrative lung disease. The importance of the pathologic approach. Sarcoidosis 1988;5:43-50.
64. Flint A, Martinez F, Young ML, Whyte RI, Toews GB, Lynch JP. Influence of sample number and biopsy site on the histologic diagnosis of diffuse lung disease. Ann Thorac Surg 1995;60:1605-8.
65. Utz JP, Ryn JH, Douglas WW, Tazelaar HD, Myers JL, Allen MS, et al. High short-term mortality following lung biopsy for usual interstitial pneumonia. Eur Respir J 2001;17:175-9.
66. Hunninghake GW, Lynch DA, Galvin JR, Gross BH, Muller N, Schwartz DA, et al. Radiological findings are strongly associated with a pathological diagnosis of usual interstitial pneumonia. Chest 2003;124:1215-23.
67. Douglas WM, Samet JM, Coultas DB. Corticosteroids and the treatment of idiopathic pulmonary fibrosis. Chest 1996;110:1058-67.
68. Bjoraker JA, Ryu JH, Edwin MK, Myers JL, Tazelaar HD, Schroeder DR, et al. Prognostic significance of histological subsets in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 1998;157:199-203.
69. Raghu G, Depaso WJ, Cain K, Hammer AP, Wetzel CE, Dreis DF, et al. Azathioprine combined with prednisone in the treatment of idiopathic pulmonary fibrosis: a prospective double-blind, randomized, placebo-controlled clinical trial. Am Rev Respir Dis 1991;144:291-6.
70. Hernandez-Cruz B, Ponce-de-Leon-Rosales S, Sifuentes-Osornio J, Ponce-de-Leon-Garduno A, Diaz-Jouanen E. Tuberculosis prophylaxis in patients with steroid treatment and systemic rheumatic diseases. A case-control study. Clin Exp Rheumatol 1999;17:81-8.
71. Lasky JA, Ortiz LA. Antifibroric therapy for the treatment of pulmonary fibrosis. Am J Med Sci 2001;322:213-21.
72. Dosanjh A, Ikonen T, Wan B, Morris RE. Pirfenidone: a novel anti-fibrotic agent and progressive chronic allograft rejection. Pulm Pharmacol Ther 2002;15:433-7.
73. Raghu G, Johnson WC, Lockhart D, Mageto Y. Treatment of idiopathic pulmonary fibrosis with a new antifibrotic agent, pirfenidone. Am J Respir Crit Care Med 1999;159:1061-9.
74. Nagai S, Hamada K, Shigematsu M, Taniyama M, Yamaauchi S, Izumi T. Open-label compassionate use one-year treatment with pirfenidone to patients with chronic pulmonary fibrosis. Intern Med 2002;41:1118-23.
75. Lortat-Jacob H, Esterre P, Grimaud JA. Interferon-gamma, an anti-fibrotic cytokine which binds to heparan sulfate. Pathol Res Pract 1994;190:920-2.
76. Ziesche R, Hofbauer E, Wittmann K, Petkov V, Block LH. A preliminary study of long-term treatment with interferon gamma-1b and low dose prednisolone in patients with idiopathic pulmonary fibrosis. N Engl J Med 1999;341:1264-9.
77. Raghu G, Brown KK, Bradford WZ, Starko K, Noble PW, Schwartz DA, et al. A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis. N Engl J Med 2004;350:125-33.
78. Cornelissen AM, Von den Hoff JW, Malta JC, Kuijpers-Jagtman AM. Effects of interferons on proliferation and collagen synthesis of rat palatal wound fibroblasts. Arch Oral Biol 1999;44:541-7.
79. Raghu G, Bozic CR, Brown K. Feasibility of a trial of interferon beta-1a in the treatment pulmonary fibrosis [abstract]. Am J Respir Crit Care Med 2001; 163:A707.
80. Douglas WW, Ryu JH, Schroeder DR. Idiopathic pulmonary fibrosis. Impact of oxygen and colchicines, prednisone, or no therapy on survival. Am J Respir Crit Care Med 2000;161:1172-8.
81. Selman M, Carrillo G, Salas J, Padilla RP, Perez-Chavira R, Sansores R, et al. Colchicine, D-penicillamine, and prednisone in the treatment of idiopathic pulmonary fibrosis: a controlled clinical trial. Chest 1998;114:507-12.
82. Geismar LS, Hennessey S, Reiser KM, Last JA. D-penicillamine prevents collagen accumulation in lungs of rats given bleomycin. Chest 1986;89:153S-4S.
83. Behr J, Maier K, Degenkolb B, Krombach F, Vogelmeier C. Antioxidant and clinical effects of high-dose N-acetylcysteine in fibrosing alveolitis. Adjunctive therapy to maintenance immunosuppression. Am J Respir Crit Care Med 1997;156:1897-901.
84. Yehualaeshet T, O'Connor R, Beleiter A, Murphy-Ullrich JE, Silverstein R, Khalil N. Administration of a synthetic peptide of the CD36 receptor reduces bleomycin-induced pulmonary inflammation and fibrosis. Am J Respir Cell Mol Biol 2000;23:204-12.
85. Molteni A, Ward WF, Ts'ao CH, Solliday NH, Dunnne M. Monocrotaline- induced pulmonary fibrosis in rats: amelioration by captopril and penicillamine. Proc Soc Exp Biol Med 1985;180:112-20.
86. Kolb M, Margetts PJ, Sime PJ, Gauldie J. Proteoglycans decorin and biglycan differentially modulate TGF-beta-mediated fibrotic responses in the lung. Am J Physiol Lung Cell Mol Physiol 2001;280:L1327-34.
87. Sugahara K, Iyama K, Kuroda MJ, Sano K. Double intratracheal instillation of keratinocyte growth factor prevents bleomycin-induced lung fibrosis in rats. J Pathol 1998;186:90-8.
88. Park SH, Saleb D, Giad A, Michel RP. Increased endothelin-1 in bleomycin-induced pulmonary fibrosis and the effects of an endothelin receptor antagonist. Am J Respir Crit Care Med 1997;156:600-8.
89. Gurujeyalakshmi G, Wang Y, Giri SN. Taurine and niacin block lung injury and fibrosis by down-regulating bleomycin-induced activation of transcription nuclear factor-kappa B in mice. J Pharmacol Exp Ther 2000;293:82-90.
90. Lok SS. Interstitial disease clinics for the management of idiopathic pulmonary fibrosis: a potential advantage to patients. J Heart Lung Transplant 1999;18:884-90.
91. Snell GI, Walters EH, Kotsimbos TC, Williams TJ. Idiopathic pulmonary fibrosis: in need of focused and systematic management. Med J Aust 2001;174:137-40.
92. Meyers BF, Lynch JP, Turlock EP, Guthrie T, Cooper JD, Patterson GA. Single versus bilateral lung transplantation for idiopathic pulmonary fibrosis: a ten-year institutional experience. J Thorac Cardiavasc Surg 2000;120:99-107.
93. Thabut G, Mal H, Castier Y, Groussard O, Brugiere O, Marrash-Chahla R, et al. Survival benefit of lung transplantation for patients with idiopathic pulmonary fibrosis. J Thoracic Cardiovasc Surg 2003;126:469-75.